Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
Nadezda Gracheva(Paul Scherrer Institute), Nicholas P. van der Meulen(Paul Scherrer Institute)
Cited by 107
Related Papers
<sup>161</sup>Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas
|Journal of Nuclear Medicine|2025|8